SCOTTSDALE, Ariz., Nov. 18, 2010 /PRNewswire/ -- Cayenne Medical, Inc., a private sports medicine device company, announces that it has reached its 50,000 implant milestone. Specializing in the soft tissue segment, Cayenne currently offers products that address previously unmet clinical needs in knee ligament reconstruction and meniscal repair, including the AperFix® System, CrossFix™ Meniscal Repair System and iFix™ System. The announcement was made today at the Arthroscopy Association of North America (AANA) 29th Fall Course in Phoenix, AZ.
"Our 50,000th implant represents an important milestone for Cayenne as it affirms the company's commitment to transform the soft tissue reconstruction segment and is proof-positive that our technology platform continues to gain significant traction throughout the orthopedic industry," said James W. Hart, President and CEO of Cayenne Medical. "We plan to continue providing innovative sports medicine solutions that offer ease-of-use for physicians and improve quality of life for patients looking to continue their active lifestyles."
The company's flagship product AperFix is a stronger, less invasive femoral and tibial fixation device for soft tissue multi-ligament repair, including the most common anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) tears. First implanted in the United States three years ago, the AperFix technology has been used by more than 1,300 surgeons in 20 countries.
The AperFix single tunnel, all-inside surgical technique attaches a soft tissue graft at the aperture (opening) of the femoral and tibial tunnels created for fixation. This creates a shorter, stiffer and more anatomic ligament reconstruction that is designed to restore natural knee kinematics. For ACL reconstruction, the technically less-demanding procedure can be performed using a traditional tibial approach or a more anatomical approach through the